Datapoint: BMS Scores New NSCLC Nod for Opdivo

March 14

The FDA on March 4 approved Bristol Myers Squibb’s Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) before surgery in the neoadjuvant setting in conjunction with platinum-doublet chemotherapy. The lightning-fast nod came within days of the agency’s priority review acceptance. As a systemic therapy for NSCLC, Opdivo holds covered or better status for 67% of all insured lives under the pharmacy benefit. 88% of all insured lives have covered or better access to Opdivo under the medical benefit.

SOURCE: MMIT Analytics, as of 3/9/22